eMedicine Specialties > Radiology > Musculoskeletal
Multiple Myeloma: Multimedia
Updated: Aug 14, 2009
Multimedia
![]() | Media file 1: Lateral radiograph of the skull. This image demonstrates numerous lytic lesions, which are typical for the appearance of widespread myeloma. |
![]() | Media file 2: Lateral radiograph of the lumbar spine. This image shows deformity of the L4 vertebral body that resulted from a plasmacytoma. |
![]() | Media file 4: Radiograph of the right humerus. This image demonstrates a destructive lesion of the diaphysis. Pathologic fracture is seen. |
![]() | Media file 7: A T2-weighted, fat-suppressed magnetic resonance image of a myeloma lesion of the humerus. This image demonstrates the lesion is hyperintense on this sequence, a typical finding. |
![]() | Media file 8: Anteroposterior radiograph of the left shoulder. This image shows an expansile process in the glenoid. |
![]() | Media file 12: A T2-weighted, fat-suppressed magnetic resonance image of the shoulder (same patient as in Images 9-11 and 13). This image demonstrates the myeloma lesion is hyperintense. |
More on Multiple Myeloma |
| Overview: Multiple Myeloma |
| Imaging: Multiple Myeloma |
| Follow-up: Multiple Myeloma |
Multimedia: Multiple Myeloma |
| References |
| Further Reading |
| « Previous Page |
References
Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. Oct 1 2007;110(7):2342-50. [Medline].
O'Sullivan P, O'Dwyer H, Flint J, Munk PL, Muller NL. Malignant chest wall neoplasms of bone and cartilage: a pictorial review of CT and MR findings. Br J Radiol. Aug 2007;80(956):678-84. [Medline].
Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. Oct 1 2007;110(7):2586-92. [Medline].
Reece DE. Management of multiple myeloma: the changing landscape. Blood Rev. Aug 28 2007;epub ahead of print. [Medline].
Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur J Radiol. Jun 2009;70(3):401-8. [Medline].
Dinter DJ, Neff WK, Klaus J, Böhm C, Hastka J, Weiss C, et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol. May 2009;88(5):457-64. [Medline].
Shortt CP, Gleeson TG, Breen KA, McHugh J, O'Connell MJ, O'Gorman PJ, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. Apr 2009;192(4):980-6. [Medline].
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. May 7 2009;[Medline].
Agool A, Slart RH, Dierckx RA, Kluin PM, Visser L, Jager PL, et al. Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. Eur J Nucl Med Mol Imaging. Jul 14 2009;[Medline].
Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. Sep-Oct 2007;57(5):301-18. [Medline]. [Full Text].
Ries LAG, Melbert D, Krapcho M, et al, eds. SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2004. Accessed September 28, 2007.
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. Sep 1975;36(3):842-54. [Medline].
Cancer reference information. What are the risk factors for multiple myeloma? Revised: 08/04/2006. American Cancer Society. Available at http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_multiple_myeloma_30.asp?sitearea=. Accessed September 28, 2007.
Schreiman JS, McLeod RA, Kyle RA, Beabout JW. Multiple myeloma: evaluation by CT. Radiology. Feb 1985;154(2):483-6. [Medline]. [Full Text].
Wiesenthal AA, Nguyen BD. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions. Clin Nucl Med. Oct 2007;32(10):797-801. [Medline].
Nanni C, Zamagni E, Cavo M, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68. [Medline]. [Full Text].
Ludwig H, Kumpan W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol. Mar 1982;55(651):173-81. [Medline].
Erten N, Saka B, Berberoglu K, et al. Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors. Ann Hematol. Nov 2007;86(11):805-13. [Medline].
Gorji J, Francis KC. Multiple myeloma. Clin Orthop Relat Res. Jan-Feb 1965;38:106-19. [Medline].
Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. Jan 1975;50(1):29-40. [Medline].
Van de Berg BC, Lecouvet FE, Michaux L, et al. Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology. Oct 1996;201(1):243-6. [Medline]. [Full Text].
Further Reading
Related eMedicine topics
Multiple Myeloma (Hematology)
Myeloma (Orthopedic Surgery)
Clinical guidelines
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. American Society of Clinical Oncology - Medical Specialty Society. 2002 Sep 1 (revised 2007 Jun 10). 9 pages. NGC:005670
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. American Society of Clinical Oncology - Medical Specialty Society
American Society of Hematology - Medical Specialty Society. 2002 Apr 18 (revised 2008 Jan 1). 18 pages. NGC:006051
Guidelines on the diagnosis and management of multiple myeloma 2005. British Committee for Standards in Haematology - Professional Association. 2006 Feb. 42 pages. NGC:005100
Clinical trials
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Previously Untreated Multiple Myeloma
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Keywords
multiple myeloma, plasma cell myeloma, myeloma, Bence-Jones protein, light chains, heavy chains, monoclonal gammopathy of unknown significance, MGUS, plasmacytoma, hypergammaglobulinemia, POEMS syndrome


























Multimedia: Multiple Myeloma